Palivizumab shows promise for preventing repeated wheezing in preemies

10/14/2013 | DailyRx.com

Babies born between 33 and 35 weeks of gestation who were given palivizumab within their first six months of life were less likely to develop recurrent wheezing during their first three years than those who did not get the medication, a Japanese study in the journal Pediatrics showed. Of the 349 babies in the palivizumab group, 6.4% had repeated wheezing compared to nearly 19% in the control group.

View Full Article in:

DailyRx.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC